About this episode

The episode discusses the latest findings from the ASH Congress, focusing on innovative therapies and studies in hematology.

People in this episode

Hosts: Dr. Richard Schabath, Dr. Andreas Hausmann

Guests: Lucy Fox, Simon Harrison, Wojciech Jurczak

Topics covered

• Latebreaking Abstracts
• CAR-T-Zelltherapien
• multiple Myelom
• ITP
• CLL
• genetic studies
• therapeutic strategies

Keywords

• ASH 2025
• Latebreaker
• CAR-T therapy
• genetic disorders
• multiple myeloma
• CLL
• ITP
• clinical relevance

Mentioned in this episode

Organizations: ASH-Kongress, IBM DX Study, Diamond-Blackfan-Anämie, KLN1010, Pirtoproteinib, Vendamustin-Rituximab, CLL, Myelom, ITP

More episodes of Hämatologie Shortcasts

• AML – Revolution oder Evolution? · February 27, 2026 · 26 min
• ASH 2025 - Aggressive B-Zell-Lymphome: Neue Optionen für ältere Patient:innen, Zelltherapien und Monitoring · February 5, 2026 · 18 min
• ASH 2025 – T-Zell-Lymphome: Neue Targets, frühe Rezidive und klinische Konsequenzen · January 19, 2026 · 29 min
• ASH 2025 – Epcoritamab & Co.: Wie sich die Therapie des follikulären Lymphoms verändert · December 19, 2025 · 20 min
• ASH 2025 - AML im Umbruch? · December 17, 2025 · 33 min
• ASH 2025 – Neuigkeiten zur CLL · December 16, 2025 · 24 min

Explore listener stats, chart rankings, contacts and more on the Hämatologie Shortcasts podcast page.